SEC Form SC 13G/A filed by Paratek Pharmaceuticals Inc. (Amendment)

$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PRTK alert in real time by email
SC 13G/A 1 nreo20230119_sc13ga.htm SCHEDULE 13G/A nreo20230119_sc13ga.htm

 

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Amendment No. 4)

 

 

 

 

Paratek Pharmaceuticals, Inc.

(Name of Issuer)

 
 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 
 

699374302

(CUSIP Number)

 
 

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

 

 

 

CUSIP No. 699374302

13G/A

Page 2 of 11

 

 

1

NAME OF REPORTING PERSONS

 

NexPoint Real Estate Opportunities, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

50,000

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

50,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

50,000

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0.09%

12

TYPE OF REPORTING PERSON*

 

 OO

 

 

 

 

 

CUSIP No. 699374302

13G/A

Page 3 of 11

 

 

1

NAME OF REPORTING PERSONS

 

Drugcrafters, LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

866,367

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

866,367

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

866,367

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

1.56%

12

TYPE OF REPORTING PERSON

 

PN

 

 

 

 

CUSIP No. 699374302

13G/A

Page 4 of 11

 

 

1

NAME OF REPORTING PERSONS

 

NexPoint Climate Tech Fund

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Massachusetts

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

64,770

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

64,770

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

64,770

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0.12%

12

TYPE OF REPORTING PERSON

 

IV

 

 

 

 

CUSIP No. 699374302

13G/A

Page 5 of 11

 

 

1

NAME OF REPORTING PERSONS

 

The Dugaboy Investment Trust

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,889,060

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,889,060

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,889,060

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

5.20%

12

TYPE OF REPORTING PERSON

 

OO

 

 

 

 

CUSIP No. 699374302

13G/A

Page 6 of 11

 

 

1

NAME OF REPORTING PERSONS

 

James D. Dondero

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

3,870,197

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

3,870,197

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

3,870,197

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

6.97%

12

TYPE OF REPORTING PERSON

 

HC, IN

 

 

 

 

CUSIP No. 699374302

13G/A

Page 7 of 11

 

 

SCHEDULE 13G

 

This amendment to Schedule 13G (this “Filing”) is being filed on behalf of NexPoint Real Estate Opportunities, LLC (“NREO”) a Delaware limited liability company, Drugcrafters, LP, a Delaware limited partnership (“Drugcrafters”), NexPoint Climate Tech Fund (f/k/a Highland Small-Cap Equity Fund) (“Climate Tech”), a Massachusetts investment company, The Dugaboy Investment Trust, a Delaware Trust (the “Trust”) and James D. Dondero (collectively, the “Reporting Persons”).

 

Item1 (a)

Name of Issuer.

 

 

Paratek Pharmaceuticals, Inc.

 

Item1 (b)

Address of Issuers Principal Executive Offices.

 

 

75 Park Plaza

 

Boston, Massachusetts 02116

 

Item2 (a)

Name of Person Filing.

 

 

(1)

NexPoint Real Estate Opportunities, LLC

 

(2)

Drugcrafters, LP

 

(3)

NexPoint Climate Tech Fund

 

(4)

The Dugaboy Investment Trust

 

(5)

James D. Dondero

 

Item 2(b)

Address of Principal Business Office, or, if none, Residence.

 

 

For all Filers:

 

 

300 Crescent Court, Suite 700

 

Dallas, Texas 75201

 

Item 2(c)

Citizenship or Place of Organization.

 

 

(1)

NexPoint Real Estate Opportunities, LLC is a Delaware limited liability company

 

(2)

Drugcrafters, LP is a Delaware limited partnership

 

(3)

NexPoint Climate Tech Fund is a Massachusetts investment company

 

(4)

The Dugaboy Investment Trust is a Delaware trust

 

(5)

James D. Dondero is a United States citizen

 

 

 

CUSIP No. 699374302

13G/A

Page 8 of 11

 

Item 2(d)

Title of Class of Securities.

 

 

Common Stock, par value $0.001 per share

 

Item 2(e)

CUSIP Number.

 

 

699374302

 

Item 3

Reporting Person.

 

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

 

 

(a)  ☐

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

 

(b)  ☐

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

 

(c)  ☐

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

 

(d)  ☒

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

 

(e)  ☐

An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

 

 

(f)  ☐

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

 

 

(g)  ☒

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

 

 

(h)  ☐

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

 

(i)  ☐

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

 

(j)  ☐

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

Item 4

Ownership.

 

 

(a)

Amount beneficially owned:

 

   

NexPoint Real Estate Opportunities, LLC: 50,000

   

Drugcrafters, LP: 866,367

   

NexPoint Climate Tech Fund: 64,770

 

 

 

CUSIP No. 699374302

13G/A

Page 9 of 11

 

   

The Dugaboy Investment Trust: 2,889,060

   

James D. Dondero: 3,870,197

 

 

(b)

Percent of Class:

 

   

NexPoint Real Estate Opportunities, LLC: 0.09%

   

Drugcrafters, LP: 1.56%

   

NexPoint Climate Tech Fund: 0.12%

   

The Dugaboy Investment Trust: 5.20%

   

James D. Dondero: 6.97%

 

 

(c)

Number of shares as to which the person has:

 

 

 

(i)          Sole power to vote or to direct the vote:

 

   

NexPoint Real Estate Opportunities, LLC: 0

   

Drugcrafters, LP: 0

   

NexPoint Climate Tech Fund: 0

   

The Dugaboy Investment Trust: 0

   

James D. Dondero: 0

 

 

 

(ii)          Shared power to vote or direct the vote:

 

   

NexPoint Real Estate Opportunities, LLC: 50,000

   

Drugcrafters, LP: 866,367

   

NexPoint Climate Tech Fund: 64,770

   

The Dugaboy Investment Trust: 2,889,060

   

James D. Dondero: 3,870,197

 

 

 

(iii)         Sole power to dispose or to direct the disposition of:

 

   

NexPoint Real Estate Opportunities, LLC: 0

   

Drugcrafters, LP: 0

   

NexPoint Climate Tech Fund: 0

   

The Dugaboy Investment Trust: 0

   

James D. Dondero: 0

 

 

 

(iv)         Shared power to dispose or to direct the disposition of:

 

   

NexPoint Real Estate Opportunities, LLC: 50,000

   

Drugcrafters, LP: 866,367

   

NexPoint Climate Tech Fund: 64,770

 

 

 

CUSIP No. 699374302

13G/A

Page 10 of 11

 

   

The Dugaboy Investment Trust: 2,889,060

   

James D. Dondero: 3,870,197

 

Item 5

Ownership of Five Percent or Less of a Class.

 

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]

 

Item 6

Ownership of More Than Five Percent on Behalf of Another Person.

 

 

Inapplicable.

 

Item 7

Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

 

 

Inapplicable.

 

Item 8

Identification and Classification of Members of the Group.

 

 

Inapplicable.

 

Item 9

Notice of Dissolution of Group.

 

 

Inapplicable.

 

Item 10

Certification.

 

 

By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

CUSIP No. 699374302

13G/A

Page 11 of 11

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date: January 20, 2023

 

NexPoint Real Estate Opportunities, LLC 

 

 

 

 

 

 

By:

/s/ Brian Mitts

 

 

 

Name: Brian Mitts 

 

 

 

Title: Authorized Signatory 

 

 

 

DRUGCRAFTERS, LP 

 

 

 

 

 

 

By:

/s/ James D. Dondero

 

 

 

Name: James D. Dondero 

 

 

 

Title: Managing Member of the

General Partner 

 

 

 

NEXPOINT CLIMATE TECH FUND 

 

 

 

 

 

 

By:

/s/ Dustin Norris

 

 

 

Name: Dustin Norris 

 

 

 

Title: Executive Vice President 

 

 

 

THE DUGABOY INVESTMENT TRUST 

 

 

 

 

 

 

By:

/s/ Nancy Dondero

 

 

 

Name: Nancy Dondero 

 

 

 

Title: Trustee 

 

 

 

/s/ James D. Dondero

 

 

James D. Dondero

 

 

 
Get the next $PRTK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PRTK

DatePrice TargetRatingAnalyst
5/2/2023$7.00 → $5.00Buy
Jefferies
4/17/2023$24.00Buy
BTIG Research
2/10/2022$11.00Buy → Strong Buy
WBB Securities
11/9/2021$28.00 → $27.00Buy
HC Wainwright & Co.
More analyst ratings

$PRTK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

    CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structu

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

    BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek's special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with th

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

    BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. ("Glass Lewis") has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings"). The Glass Lewis recommendation follows the recent receipt of the recommendation from Institutional Shareholder Services Inc. (

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PRTK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PRTK
SEC Filings

See more

$PRTK
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for NUZYRA

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Leadership Updates

Live Leadership Updates

See more
  • Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

    BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operational track record, and demonstrated independent judgment, integrity and commitment to the role. Having served as a director of Paratek since its emergence as a public company in 2014, Dr. Stein

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

    NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

    $APYX
    $LNTH
    $PRTK
    $SCPH
    Medical/Dental Instruments
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Pharmaceutical Preparations
  • Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management

    - Evan Loh, M.D., Jonathan Leff, and Jana Jensen, Ph.D., Appointed Directors of APT - Adaptive Phage Therapeutics, Inc. ("APT"), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company's Board of Directors. "We are delighted to welcome Evan, Jonathan, and Jana to APT's Board, as we expand our team following the successful completion of our $40.75 million Series B financing," said Greg Merril, A

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Financials

Live finance-specific insights

See more
  • Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

    -- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), ("Paratek" or "the Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today reported financial results and provided an update on corpora

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

    -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats fo

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9

    BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9About Paratek Phar

    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PRTK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more